"People are starting to retire, and there isn't that much production of urologists every year; there's about 270 that come out for the whole country," says Richard Harris, MD.
In this interview, Richard Harris, MD, FACS, discusses some of the biggest challenges facing urology practices today, including those with staffing and regulations. Harris is the CEO and President of UroPartners and a practicing urologist in Chicago, Illinois. He was interviewed at the 2022 LUGPA Annual Meeting held in Chicago.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.